# Evolus, Inc.

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/Evolus, Inc.).

## Overview

Evolus, Inc. is a U.S.-based performance beauty company focused on cash-pay medical aesthetics. It commercializes Jeuveau®, a botulinum toxin for glabellar lines, and has begun launching Evolysse™, a line of injectable hyaluronic acid gels for wrinkles and folds.

## Products & services

• Jeuveau® botulinum toxin for glabellar lines
• Evolysse™ Form injectable HA gel
• Evolysse™ Smooth injectable HA gel
• Evolysse™ Sculpt injectable HA gel candidate
• Evolysse™ Lips injectable HA gel candidate
• Consumer loyalty and co-branded marketing programs

- **Injectable neurotoxins** (85%) — Jeuveau® is the company's commercial botulinum toxin product used by aesthetic practitioners for glabellar lines.
- **Injectable hyaluronic acid gels** (15%) — Evolysse™ is a collection of HA fillers for wrinkles, folds, and facial contour applications.
- **Commercial support programs** (0%) — Loyalty, pricing, and co-branded marketing programs that support practitioner adoption and repeat purchasing.

- Jeuveau® botulinum toxin for temporary improvement of frown lines
- Evolysse™ Form injectable hyaluronic acid gel
- Evolysse™ Smooth injectable hyaluronic acid gel
- Evolysse™ Sculpt injectable hyaluronic acid gel candidate
- Evolysse™ Lips injectable hyaluronic acid gel candidate
- Consumer loyalty, promotional, and co-branded marketing programs

## Customers

Evolus sells primarily to licensed aesthetic practitioners who administer injectable treatments in the cash-pay beauty market. Demand is driven by clinics and providers seeking differentiated products, marketing support, and flexible pricing rather than reimbursement-based therapeutic products. The company also indirectly serves end consumers who pay out of pocket for aesthetic procedures.

- **Licensed aesthetic practitioners** (primary) — Buy Jeuveau® and Evolysse™ to perform elective injectable treatments and retain patients in cash-pay aesthetics.
- **Medical spas and aesthetic clinics** (primary) — Purchase products for recurring facial aesthetic procedures and respond to pricing, loyalty, and bundled offers.
- **Dermatology and plastic surgery practices** (secondary) — Use the products as part of broader aesthetic service menus and value clinical data and product differentiation.
- **International distribution partners** (secondary) — Help commercialize Jeuveau® and future Evolysse™ launches outside the U.S. where direct sales are not used.

- Licensed aesthetic practitioners buy products for in-office injections
- Medical spas and dermatology/plastic surgery clinics are core accounts
- Practitioners value product performance, training, and marketing support
- Consumers pay cash for elective aesthetic procedures
- International distributors/partners support markets outside the U.S.

## Geography

Evolus is headquartered in the United States and generates most revenue there, with Jeuveau® also sold in Canada, certain European countries, and Australia. The company launched Evolysse™ Form and Smooth in the U.S. in April 2025 and expects broader European launches in 2026, making international approvals and market access important to growth.

- **United States** (0%) — Company states the U.S. is the primary market, but no country revenue split was disclosed.
- **Canada** (0%) — Canada is served through a distribution partner; no country revenue split was disclosed.
- **Europe** (0%) — Certain European countries are served and Europe is a planned launch region for Evolysse™.
- **Australia** (0%) — Jeuveau® is sold in Australia; no revenue split was disclosed.

- United States is the main commercial market for Jeuveau® and Evolysse™
- Canada contributes service revenue through a distribution partner
- Certain European countries and Australia are current Jeuveau® markets
- Europe is a key expansion market for the Evolysse™ collection
- Manufacturing is outsourced to South Korea and France

## Strategy

Evolus is building a cash-pay aesthetics franchise around Jeuveau® and the Evolysse™ filler line, using an aesthetic-only model to avoid reimbursement complexity and preserve pricing flexibility. Its strategy combines U.S. expansion, international launches, and digital customer engagement to grow practitioner adoption and broaden the product portfolio.

- **Grow Jeuveau® adoption in the U.S. and abroad** (short-term) — Jeuveau® is the core commercial product and funds the platform.
- **Scale Evolysse™ in the U.S. and Europe** (medium-term) — The HA filler line expands the addressable market and diversifies revenue.
- **Expand the product portfolio through approvals and partnerships** (medium-term) — A broader portfolio improves customer retention and competitive positioning.

- Focus on large, fast-growing injectable aesthetics categories
- Use an aesthetic-only model to preserve pricing and marketing flexibility
- Expand Jeuveau® and Evolysse™ through direct and partner-led launches
- Leverage digital tools to open accounts and support repeat purchasing
- Broaden the portfolio through in-licensing, partnerships, and acquisitions

## Risks

Evolus depends on continued adoption of elective aesthetic procedures, so consumer spending weakness, inflation, and tariffs can pressure demand and margins. The company also faces execution risk around regulatory approvals, international launches, and reliance on third-party manufacturers and partners for supply and commercialization.

- **Dependence on elective consumer spending** [high] — Customers pay out of pocket, so demand is sensitive to confidence, inflation, and economic stress.
- **Tariffs and supply-chain cost inflation** [high] — The company imports products and components through third-party manufacturers, making costs vulnerable to trade actions.
- **Regulatory approval and launch timing** [high] — Future Evolysse™ products require FDA and other approvals before commercialization.
- **Manufacturing concentration** [medium] — Jeuveau® and Evolysse™ rely on Daewoong and Symatese for production and supply.
- **Competitive pricing pressure** [medium] — Large aesthetics competitors can use rebates, coupons, and bundling to defend share.

- Consumer discretionary demand can weaken in a cash-pay market
- Tariffs and inflation can raise input and logistics costs
- Regulatory approval timing may delay Evolysse™ launches
- Reliance on third-party manufacturers creates supply-chain exposure
- Competition can intensify through pricing, rebates, and bundling

## Accounting

Revenue is recognized when control of Jeuveau® or Evolysse™ transfers to the customer, while Canadian distribution activity is recorded as service revenue on a net basis. Investors should watch the impact of rebates, loyalty rewards, co-branded marketing programs, and the fair-value remeasurement of the contingent royalty obligation, all of which can materially affect reported margins and operating expenses.

- **Revenue recognition and net revenue adjustments** — Net revenue and gross margin
- **Service revenue in Canada** — Revenue mix and margin presentation
- **Contingent royalty obligation fair value** — Operating expenses and balance sheet liabilities
- **Inventory and launch-related build** — Working capital and cash flow

- Revenue is recognized at transfer of control for product sales
- Canadian distribution partner sales are recorded as service revenue
- Rebates and loyalty programs reduce net revenue
- Contingent royalty obligation is remeasured each period
- Inventory build for launches and tariffs affects working capital

---

*Last updated: 2026-04-28T20:05:41.501176+00:00*